Abstract
Stimulating growth factor expressed by gene 2 (ST2) and natriuretic peptides (BNP and NT-proBNP) reflect the flow of two different, but intersecting biological processes, so the markers provide independent and complementary information on the patient’s condition. Being markers of hemodynamic instability or stretching of cardiomyocytes NT-proBNP/BNP is more suitable for detecting chronic heart failure, but this is not enough to rehospitalize patients for 30 days with the predictive qualities of this marker. ST2 is the strongest and clinically significant prognostic marker of cumulative cardiovascular events and mortality. The use of new highly specific cardiobiomarkers will make it possible to predict the development of cardiovascular complications with a high degree of predictive value, and therefore will allow prophylactically prescribing appropriate pathogenetic therapy aimed at improving the quality of life of patients, reducing mortality from cardiovascular diseases and reducing the economic costs of the state for treating heart failure and cardiovascular complications.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
